Condition: Relapsed Cancer · Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype · Sponsor: University Hospital, Bordeaux
Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol). The aim of this study is to better characterize transcriptomic, proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor, in order to identify new prognostic markers and potential new therapeutic targets.
This description comes directly from the study's public registry record.
Mathieu LARROQUETTE · +33 5 56 79 58 08 · mathieu.larroquette@chu-bordeaux.fr
Julien ENGELHARDT · julien.engelhardt@chu-bordeaux.fr
Always discuss trial participation with your own doctor first.
| CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médicale | Bordeaux, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06430424